Fenfluramine in SCN1A ‐related GEFS +: A multicenter observational study on efficacy, EEG improvement, and tolerability
Epilepsia Open · 2026-04 · 11 (2) · 619-626
DOI: 10.1002/epi4.70187 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia Open, online erschienen am 25.02.2026. Verfasst von Giovanni B Dell'Isola und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Developmental Disabilities, IRCCS San Raffaele Roma, Rome, Italy. Hauptthemen laut MEDLINE: NAV1.1 Voltage-Gated Sodium Channel, Fenfluramine, Anticonvulsants, Epilepsy, Generalized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
The SCN1A gene is implicated in a broad spectrum of epilepsy phenotypes, ranging from self‐limited genetic epilepsy with febrile seizures plus (GEFS+) to severe developmental and epileptic encephalopathies such as Dravet syndrome (DS). While fenfluramine (FFA) has demonstrated strong efficacy in DS, its role in SCN1A ‐related epilepsies beyond DS has not been thoroughly investigated. We conducted a multicenter observational study including 11 patients with SCN1A ‐related GEFS+ who received FFA as adjunctive therapy. All patients had previously failed to achieve adequate seizure control with valproate and, in most cases, additional antiseizure medications. FFA was introduced following the DS titration protocol, with a mean dose of 0.39 mg/kg/day. FFA addition led to a mean seizure frequency reduction of 91%, with more than half of the patients achieving complete seizure freedom. Reduced EEG abnormalities were documented in 5/11 patients of the cohort, including complete normalization in 3/11 patients. Furthermore, subjective caregiver reports indicated perceived improvements in patients' alertness and behavioral responses. FFA was well tolerated, with only mild and transient adverse events reported. These findings support the potential role of FFA as an effective and well‐tolerated treatment option in patients with SCN1A ‐related GEFS+. Plain Language Summary GEFS+ is a genetic epilepsy frequently caused by changes in the SCN1A gene. In a multicenter real‐world study of 11 people with SCN1A‐related GEFS+, adding fenfluramine to usual care substantially reduced seizures, with several becoming seizure‐free. EEG recordings improved, and caregivers reported better alertness in some patients. Treatment was generally well tolerated, with only mild, temporary side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Developmental Disabilities, IRCCS San Raffaele Roma, Rome, Italy.
- Department of Medicine and Surgery, Saint Camillus International University of Health Sciences, Rome, Italy.
- Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
- Paediatric Neurology and Psychiatry Unit, Spedali Civili Children's Hospital, University of Brescia, Brescia, Italy.
- Neuroscience and Medical Genetics Department, Meyer Children's Hospital IRCCS, European Reference Network for Rare and Complex Epilepsies (EpiCARE), Florence, Italy.
- NEUROFARBA Department, University of Florence, Florence, Italy.
ORCID-Profile: Alice Muda, Francesca Bisulli, Pasquale Striano
Förderung
- Ministero della Salute
Zitieren
APA
Dell'Isola, G. B., Muda, A., Giordano, L., Guerrini, R., Boncristiano, A., Pietrafusa, N., Polselli, M., Bisulli, F., Ragona, F., Riva, A., Striano, P., Battaglia, D. I., & Vigevano, F. (2026). Fenfluramine in SCN1A ‐related GEFS +: A multicenter observational study on efficacy, EEG improvement, and tolerability. Epilepsia Open, 11(2), 619-626. https://doi.org/10.1002/epi4.70187
Vancouver
Dell'Isola GB, Muda A, Giordano L, Guerrini R, Boncristiano A, Pietrafusa N, et al. Fenfluramine in SCN1A ‐related GEFS +: A multicenter observational study on efficacy, EEG improvement, and tolerability. Epilepsia Open. 2026;11(2):619-626. doi:10.1002/epi4.70187
BibTeX
@article{DellIsola2026,
author = {Dell'Isola, Giovanni B and Muda, Alice and Giordano, Lucio and Guerrini, Renzo and Boncristiano, Alessandra and Pietrafusa, Nicola and Polselli, Maria and Bisulli, Francesca and Ragona, Francesca and Riva, Antonella and Striano, Pasquale and Battaglia, Domenica Immacolata and Vigevano, Federico},
title = {Fenfluramine in SCN1A ‐related GEFS +: A multicenter observational study on efficacy, EEG improvement, and tolerability},
journal = {Epilepsia Open},
year = {2026},
volume = {11},
number = {2},
pages = {619--626},
doi = {10.1002/epi4.70187}
}
EUVIMED